Abstract CT014: Perioperative adebrelimab (A) plus chemotherapy (chemo) in resectable stage II-III NSCLC: Phase 3 EFS interim analysis (IA) and molecular residual disease (MRD) analysis
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Yi-Long Wu, Wen-Zhao Zhong, Li-Xu Yan, Keneng Chen, Wanpu Yan, Yongzhong Luo, Wenxiang Wang, Wenqun Xing, Xiaolong Yan, Lin Wu, Feng Yao, Dongsheng Yue, Naiquan Mao, Yu Qi, Bentong Yu, Jianji Guo, Jindan Kai, Yuejun Chen, Hui Wang, Qin Zhang, Lunxu Liu, Honghai Wang, Yuanyuan Ji, Yongtao Han, Yongxiang Song, Jianjun Xu, Wei Guo, Hongxu Liu, Di Ge, Hecheng Li, XiuJuan Qu, Jifang Yao, Junfeng Liu, Tingyan Zhong, Yanhua Huang, Li Song, Wei Shi
Institutions: Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University, Peking University Cancer Hospital, Hunan Cancer Hospital, Henan Cancer Hospital, Air Force Medical University, Shanghai Chest Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Nanchang University, First Affiliated Hospital of GuangXi Medical University, Hubei Cancer Hospital, Anyang Tumor Hospital, Jiangsu Cancer Hospital, West China Hospital of Sichuan University, Sichuan Cancer Hospital, Zunyi Medical University, Second Affiliated Hospital of Nanchang University, Liaoning Cancer Hospital & Institute, Shanghai Medical College of Fudan University, Fudan University, Zhongshan Hospital, Shanghai Jiao Tong University, Ruijin Hospital, First Hospital of China Medical University, Hebei Medical University, Fourth Hospital of Hebei Medical University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154724754